Topotecan in Glioma Undergoing A Clinically-Indicated Surgical Resection

EARLY_PHASE1TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

July 6, 2015

Primary Completion Date

November 19, 2018

Study Completion Date

November 19, 2018

Conditions
Brain TumorHigh Grade Glioma
Interventions
DRUG

topotecan

intraparenchymally-administered topotecan will use the Cleveland Multiport Catheter to directly infuse topotecan into the tumor site of patients with suspected recurrent/progressive high grade glioma (HGG). This drug is already FDA approved to be administered intravenously.

DEVICE

Cleveland Multiport Catheter

The Cleveland Multiport Catheter will directly infuse topotecan into the tumor site of patients with suspected recurrent/progressive high grade glioma (HGG). Standard treatment is to adminsiter the drug intravenously.

Trial Locations (1)

44195

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

Sponsors
All Listed Sponsors
collaborator

Infuseon Therapeutics, Inc.

INDUSTRY

lead

Michael Vogelbaum, MD, PhD

OTHER